Acquisition by Cleaver Heath of 2000 shares of Bio Path at 1.55 subject to Rule 16b-3
| BPTHDelisted Stock | USD 0.19 0.01 5.00% |
Under 61% of Bio Path's investor base is looking to short. The analysis of overall sentiment of trading Bio Path Holdings otc stock suggests that many investors are alarmed at this time. Bio Path's investing sentiment shows overall attitude of investors towards Bio Path Holdings.
Bio |
Filed transaction by Bio Path Holdings Director. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Bio Path Fundamental Analysis
We analyze Bio Path's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bio Path using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bio Path based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
Bio Path is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Bio Path Holdings Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Bio Path otc stock to make a market-neutral strategy. Peer analysis of Bio Path could also be used in its relative valuation, which is a method of valuing Bio Path by comparing valuation metrics with similar companies.
Peers
Bio Path Related Equities
| BNTC | Benitec Biopharma | 11.39 | ||||
| CRNX | Crinetics Pharmaceuticals | 7.74 | ||||
| CAPR | Capricor Therapeutics | 6.95 | ||||
| PULM | Pulmatrix | 4.66 | ||||
| ACHV | Achieve Life | 3.37 | ||||
| MBRX | Moleculin Biotech | 1.57 | ||||
| NXTC | NextCure | 1.30 | ||||
| AKTX | Akari Therapeutics | 3.33 |
Check out Bio Path Hype Analysis, Bio Path Correlation and Bio Path Performance. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Other Consideration for investing in Bio OTC Stock
If you are still planning to invest in Bio Path Holdings check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bio Path's history and understand the potential risks before investing.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |